New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:34 EDTINCYIncyte duration of response not an issue, says Jefferies
Jefferies says the shorter than expected duration of response for Incyte's '360 with ipilimumab is not an issue since the progression-free survival number is strong. Jefferies believes last night's data suggests that '360 offers up to three times the clinical benefit expected with ipilimumab alone. It maintains a Buy rating on Incyte shares with an $80 price target.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 23, 2015
12:35 EDTINCYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:55 EDTINCYIncyte management to meet with JPMorgan
Subscribe for More Information
August 18, 2015
08:41 EDTINCYIncyte shares poised to advance further, says Argus
Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use